Former Chief Medical Officer · Kyverna Therapeutics, Inc. (KYTX)

James Chung

FY2024 is the first fiscal year CompBrief holds for James Chung as a named executive officer of Kyverna Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$624,576

Salary $404,576Stock awards $0

3rd of 5 named executive officers at Kyverna Therapeutics by FY2024 total.

5 named officers on file for Kyverna Therapeutics, FY2024

James Chung’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kyverna Therapeutics’s whole pay program stands against its peers

  • Kyverna Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KYTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 14, 2025 (DEF 14A).

Free

Get James Chung’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

James Chung compensation by year

Kyverna Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Kyverna Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$404,576
Bonus$0
Stock awards$0
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$220,000
Total$624,576

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kyverna Therapeutics, Inc. DEF 14A filed April 14, 2025, accession 0000950170-25-053699, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kyverna Therapeutics, Inc. filed document, accession 0000950170-25-053699. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2025.

Kyverna Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Warner BiddleChief Executive Officer$14,992,897
Peter MaagFormer Chief Executive Officer$1,481,230
James Chung · this pageFormer Chief Medical Officer$624,576
Karen WalkerChief Technology Officer$591,360
Dominic BorieFormer President, Research and Development$587,840

The full Kyverna Therapeutics compensation record

free company brief

This page is one person within Kyverna Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kyverna Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

James Chung's compensation dossier · One-time report. No refunds.